Drug Profile
Phortress
Alternative Names: 5F 203 prodrug; NSC-710305Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cancer Research UK
- Developer Pharminox
- Class Antineoplastics; Small molecules; Thiazoles
- Mechanism of Action Apoptosis stimulants; Cytochrome P-450 enzyme system stimulants; DNA cross linking agents; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in United Kingdom (IV-injection, Injection)
- 20 Dec 2006 Phortress is still in phase I trials for Cancer in United Kingdom
- 04 May 2004 Phase-I clinical trials in Cancer in United Kingdom (IV-injection)